After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly include India's Cipla and Lupin. Sources tell Bloomberg that the two Indian drugmakers were among others to make first-round bids for Kremers Urban Pharmaceuticals. UCB in December canceled its deal with private equity investors Advent International and Avista Capital Partners after the FDA asked Kremers Urban for an additional study on its copy of Johnson & Johnson's ($JNJ) Concerta pill for attention deficit hyperactivity disorder (ADHD) to insure its equivalency. UCB said it needed to clear up the regulatory issues. Report | More